RUBY News and Press, Rubius Therapeutics Inc. From 07/22/21

CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the tr...

CAMBRIDGE, Mass., July 15, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced...

Today, we take our first in-depth look at Rubius Therapeutics which has developed a new class of cellular therapies called Red Cell Therapeutics. The company's pipeline has several candidates in development and Rubius recently addressed its current funding needs. A full investment...

Rubius Therapeutics (RUBY) announces that the first patient has been dosed in a new Phase 1 arm of the ongoing Phase 1/2 clinical trial of RTX-240 in combination with Merck's KEYTRUDA (pembrolizumab) for the treatment of patients with relapsed/refractory or locally advanced solid tu...

CAMBRIDGE, Mass., June 23, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced...

Chip Somodevilla/Getty Images News Stephen Hahn, an oncologist who served as FDA commissioner as the Trump administration dealt with the COVID-19 pandemic, has joined venture capital firm Flagship Pioneering as a chief medical officer. Hahn will lead Flagship's Preemptive Medicine and Health ...

Dr. Stephen Hahn, 24th US FDA Commissioner and Former Chief Medical Executive at MD Anderson, joins Flagship Pioneering as Chief Medical Officer of Flagship's Preemptive Medicine and Health Security Initiative PR Newswire CAMBRIDGE, Mass. , June 14, 2021 /PRNewsw...

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to invest in multiple biotech companies via one vehicle. The life science sector certainly holds a risk factor, and ETFs are a good wa...

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture PR Newswire CAMBRIDGE, Mass. , May 25, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's in...